IM CANNABIS CORP (IMCC)

CA44969Q4060 - Common Stock

2.49  -0.13 (-4.96%)

Fundamental Rating

2

Taking everything into account, IMCC scores 2 out of 10 in our fundamental rating. IMCC was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IMCC have multiple concerns. While showing a medium growth rate, IMCC is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

IMCC had negative earnings in the past year.
In the past year IMCC had a positive cash flow from operations.
In the past 5 years IMCC always reported negative net income.
In the past 5 years IMCC always reported negative operating cash flow.

1.2 Ratios

IMCC has a Return On Assets (-28.82%) which is comparable to the rest of the industry.
The Return On Equity of IMCC (-216.04%) is worse than 70.65% of its industry peers.
Industry RankSector Rank
ROA -28.82%
ROE -216.04%
ROIC N/A
ROA(3y)-112.32%
ROA(5y)-148.76%
ROE(3y)-302.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

IMCC has a Gross Margin of 12.87%. This is comparable to the rest of the industry: IMCC outperforms 50.00% of its industry peers.
The Profit Margin and Operating Margin are not available for IMCC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IMCC has more shares outstanding
The number of shares outstanding for IMCC has been increased compared to 5 years ago.
The debt/assets ratio for IMCC is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -8.00, we must say that IMCC is in the distress zone and has some risk of bankruptcy.
IMCC has a worse Altman-Z score (-8.00) than 70.11% of its industry peers.
The Debt to FCF ratio of IMCC is 5.69, which is a neutral value as it means it would take IMCC, 5.69 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 5.69, IMCC belongs to the best of the industry, outperforming 86.41% of the companies in the same industry.
IMCC has a Debt/Equity ratio of 2.24. This is a high value indicating a heavy dependency on external financing.
IMCC has a worse Debt to Equity ratio (2.24) than 80.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.24
Debt/FCF 5.69
Altman-Z -8
ROIC/WACCN/A
WACC12.65%

2.3 Liquidity

IMCC has a Current Ratio of 0.70. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
IMCC has a worse Current ratio (0.70) than 95.65% of its industry peers.
IMCC has a Quick Ratio of 0.70. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
IMCC's Quick ratio of 0.52 is on the low side compared to the rest of the industry. IMCC is outperformed by 95.11% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.52

More info and screens

4

3. Growth

3.1 Past

IMCC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -172.51%.
IMCC shows a decrease in Revenue. In the last year, the revenue decreased by -2.23%.
Measured over the past years, IMCC shows a very strong growth in Revenue. The Revenue has been growing by 45.36% on average per year.
EPS 1Y (TTM)-172.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-156.25%
Revenue 1Y (TTM)-2.23%
Revenue growth 3Y45.36%
Revenue growth 5YN/A
Sales Q2Q%12.23%

3.2 Future

IMCC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.27% yearly.
The Revenue is expected to grow by 19.84% on average over the next years. This is quite good.
EPS Next Y-314.48%
EPS Next 2Y1.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.16%
Revenue Next 2Y19.84%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMCC. In the last year negative earnings were reported.
Also next year IMCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, IMCC is valued cheaper than 98.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.03
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.27%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMCC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IM CANNABIS CORP

NASDAQ:IMCC (1/8/2025, 8:09:22 PM)

2.49

-0.13 (-4.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners6.37%
Inst Owner Change0%
Ins Owners30.19%
Ins Owner ChangeN/A
Market Cap7.69M
Analysts82.86
Price TargetN/A
Short Float %1.67%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.16%
Min EPS beat(2)71.55%
Max EPS beat(2)80.78%
EPS beat(4)2
Avg EPS beat(4)0.03%
Min EPS beat(4)-105.88%
Max EPS beat(4)80.78%
EPS beat(8)4
Avg EPS beat(8)-51.04%
EPS beat(12)4
Avg EPS beat(12)-431.99%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-12.75%
Max Revenue beat(2)9.9%
Revenue beat(4)3
Avg Revenue beat(4)2.27%
Min Revenue beat(4)-12.75%
Max Revenue beat(4)11.57%
Revenue beat(8)3
Avg Revenue beat(8)-1.99%
Revenue beat(12)4
Avg Revenue beat(12)-6.98%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-285.71%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)11.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.22
P/FCF 4.03
P/OCF 3.81
P/B 1.86
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)0.62
FCFY24.84%
OCF(TTM)0.65
OCFY26.23%
SpS11.56
BVpS1.34
TBVpS-0.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.82%
ROE -216.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.87%
FCFM 5.35%
ROA(3y)-112.32%
ROA(5y)-148.76%
ROE(3y)-302.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 2.24
Debt/FCF 5.69
Debt/EBITDA N/A
Cap/Depr 6.49%
Cap/Sales 0.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.52
Altman-Z -8
F-Score5
WACC12.65%
ROIC/WACCN/A
Cap/Depr(3y)40.3%
Cap/Depr(5y)133.94%
Cap/Sales(3y)5.85%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-172.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-156.25%
EPS Next Y-314.48%
EPS Next 2Y1.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.23%
Revenue growth 3Y45.36%
Revenue growth 5YN/A
Sales Q2Q%12.23%
Revenue Next Year19.16%
Revenue Next 2Y19.84%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y133.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y154.17%
OCF growth 3YN/A
OCF growth 5YN/A